{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:18:51Z","timestamp":1771237131460,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T00:00:00Z","timestamp":1514332800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100015542","name":"GSK Japan","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015542","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s40261-017-0602-4","type":"journal-article","created":{"date-parts":[[2017,12,27]],"date-time":"2017-12-27T14:20:39Z","timestamp":1514384439000},"page":"219-229","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Surveillance on The Safety and Efficacy of Ambrisentan (Volibris Tablet 2.5 mg) in Patients with Pulmonary Arterial Hypertension in Real Clinical Practice: Post-marketing Surveillance (Interim Analysis Report)"],"prefix":"10.1007","volume":"38","author":[{"given":"Tomohiko","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Hayata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Onaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Ebihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terufumi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,27]]},"reference":[{"issue":"5","key":"602_CR1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D\u2019Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343\u20139.","journal-title":"Ann Intern Med."},{"issue":"4","key":"602_CR2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1378\/chest.15-0300","volume":"148","author":"HW Farber","year":"2015","unstructured":"Farber HW, Miller DP, Poms AD, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. CHEST. 2015;148(4):1043\u201354.","journal-title":"CHEST."},{"issue":"3","key":"602_CR3","first-page":"129","volume":"69","author":"S Akagi","year":"2015","unstructured":"Akagi S, Nakamura K, Matsubara H, et al. Epoprostenol therapy for pulmonary arterial hypertension. Acta Med Okayama. 2015;69(3):129\u201336.","journal-title":"Acta Med Okayama."},{"issue":"5","key":"602_CR4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/MCP.0000000000000308","volume":"22","author":"Y Tamura","year":"2016","unstructured":"Tamura Y, Channick RN. New paradigm for pulmonary arterial hypertension treatment. Curr Opin Pulm Med. 2016;22(5):429\u201333.","journal-title":"Curr Opin Pulm Med."},{"issue":"1","key":"602_CR5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/thoraxjnl-2015-207170","volume":"71","author":"M Humbert","year":"2016","unstructured":"Humbert M, Ghofrani HA. The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax. 2016;71(1):73\u201383.","journal-title":"Thorax."},{"issue":"1","key":"602_CR6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119.","journal-title":"Eur Heart J."},{"issue":"9","key":"602_CR7","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1185\/03007995.2015.1074890","volume":"31","author":"AJ Peacock","year":"2015","unstructured":"Peacock AJ, Zamboni W, Vizza CD. Ambrisentan for the treatment of adults with pulmonary arterial hypertension: a review. Curr Med Res Opin. 2015;31(9):1793\u2013807.","journal-title":"Curr Med Res Opin."},{"key":"602_CR8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","volume":"135","author":"MD McGoon","year":"2009","unstructured":"McGoon MD, Frost ME, Oudiz RJ. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. CHEST. 2009;135:122\u20139.","journal-title":"CHEST."},{"issue":"1","key":"602_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cts.12382","volume":"9","author":"A Hakamata","year":"2016","unstructured":"Hakamata A, Odagiri K, Miyakawa S, et al. Pharmacokinetic and pharmacodynamic comparison of sildenafil-bosentan and sildenafil-ambrisentan combination therapies for pulmonary hypertension. Clin Transl Sci. 2016;9(1):29\u201335.","journal-title":"Clin Transl Sci."},{"issue":"9","key":"602_CR10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1185\/03007995.2011.605440","volume":"27","author":"S Yoshida","year":"2011","unstructured":"Yoshida S, Shirato K, Shimamura R, et al. Efficacy, safety, and pharmacokinetics of ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2011;27(9):1827\u201334.","journal-title":"Curr Med Res Opin."},{"key":"602_CR11","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Gali\u00e8","year":"2008","unstructured":"Gali\u00e8 N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010\u20139.","journal-title":"Circulation."},{"key":"602_CR12","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1016\/j.jacc.2009.07.033","volume":"54","author":"RJ Oudiz","year":"2009","unstructured":"Oudiz RJ, Gali\u00e8 N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54:1971\u201381.","journal-title":"J Am Coll Cardiol."},{"key":"602_CR13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1185\/03007995.2012.685930","volume":"28","author":"S Yoshida","year":"2012","unstructured":"Yoshida S, Shirato K, Shimamura R, et al. Long-term safety and efficacy of ambrisentan in Japanese adults with pulmonary arterial hypertension. Curr Med Res Opin. 2012;28:1069\u201376.","journal-title":"Curr Med Res Opin."},{"issue":"1","key":"602_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00002727-200701000-00004","volume":"30","author":"GL Traiger","year":"2007","unstructured":"Traiger GL. Pulmonary arterial hypertension. Crit Care Nurs Q. 2007;30(1):20\u201343.","journal-title":"Crit Care Nurs Q."},{"issue":"4","key":"602_CR15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.healun.2016.04.013","volume":"36","author":"JL Vachi\u00e9ry","year":"2017","unstructured":"Vachi\u00e9ry JL, Hoeper MM, Peacock AJ, et al. Ambrisentan use for pulmonary arterial hypertension in a post-authorization drug registry: The VOLibris tracking study. J Heart Lung Transplant. 2017;36(4):399\u2013406.","journal-title":"J Heart Lung Transplant."},{"key":"602_CR16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1253\/circj.69.131","volume":"69","author":"S Sasayama","year":"2005","unstructured":"Sasayama S, Kunieda T, Tomoike H, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension. Circ J. 2005;69:131\u20137.","journal-title":"Circ J."},{"issue":"6","key":"602_CR17","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1253\/circj.CJ-15-1305","volume":"80","author":"N Tahara","year":"2016","unstructured":"Tahara N, Dobashi H, Fukuda K, et al. Efficacy and safety of a novel endothelin receptor antagonist, macitentan, in Japanese patients with pulmonary arterial hypertension. Circ J. 2016;80(6):1478\u201383.","journal-title":"Circ J."},{"issue":"9","key":"602_CR18","doi-asserted-by":"crossref","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","volume":"158","author":"G Raghu","year":"2013","unstructured":"Raghu G, Behr J, Brown KK, Egan JJ, et al. Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial. Ann Intern Med. 2013;158(9):641\u20139.","journal-title":"Ann Intern Med."},{"key":"602_CR19","unstructured":"Efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP) (RISE-IIP)\u201d (NCT02138825). In: Clinicaltrial.gov. \n                        https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02138825?term=riociguat&cond=IIP&rank=1\n                        \n                    . Accessed Oct 2017."},{"issue":"1","key":"602_CR20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1164\/rccm.201011-1874OC","volume":"184","author":"TE King Jr","year":"2011","unstructured":"King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(1):92\u20139.","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"602_CR21","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1183\/09031936.00104612","volume":"42","author":"G Raghu","year":"2013","unstructured":"Raghu G, Million-Rousseau R, Morganti A, et al. Macitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial and Supplementary material. Eur Respir J. 2013;42(6):1622\u201332.","journal-title":"Eur Respir J."},{"issue":"2","key":"602_CR22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11926-015-0560-x","volume":"18","author":"V Sobanski","year":"2016","unstructured":"Sobanski V, Launay D, Hachulla E, et al. Current approaches to the treatment of systemic-sclerosis-associated pulmonary arterial hypertension (SSc-PAH). Curr Rheumatol Rep. 2016;18(2):10.","journal-title":"Curr Rheumatol Rep."},{"issue":"4","key":"602_CR23","first-page":"492","volume":"3","author":"Y Ichimura","year":"2014","unstructured":"Ichimura Y, Tanabe N, Tatsumi K. The progress of diagnosis and therapy in pulmonary hypertension due to interstitial pneumonia. Ann Jpn Respir Soc. 2014;3(4):492\u20137 (in Japanese).","journal-title":"Ann Jpn Respir Soc."},{"issue":"25 Suppl","key":"602_CR24","doi-asserted-by":"crossref","first-page":"D109","DOI":"10.1016\/j.jacc.2013.10.036","volume":"62","author":"W Seeger","year":"2013","unstructured":"Seeger W, Adir Y, Barber\u00e0 JA, et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol. 2013;62(25 Suppl):D109\u201316.","journal-title":"J Am Coll Cardiol."},{"key":"602_CR25","unstructured":"Nakanishi N, Ando T, Ueda H, et al. Guidelines for Treatment of Pulmonary Hypertension (JCS2012. 2nd edn. The Japanese Circulation Society; 2012 (in Japanese)"},{"key":"602_CR26","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834\u201344.","journal-title":"N Engl J Med."},{"key":"602_CR27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s00380-014-0544-1","volume":"30","author":"M Hatano","year":"2015","unstructured":"Hatano M, Yamada H, Fukuda K, et al. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension. Heart Vessels. 2015;30:798\u2013804.","journal-title":"Heart Vessels."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0602-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0602-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T19:47:59Z","timestamp":1589831279000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0602-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,27]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0602-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,27]]}}}